Stem-cell board too close to industry, critics worry
By San Jose Mercury News,
San Jose Mercury News
| 05. 19. 2005
California's new stem-cell institute is poised to begin spending $3 billion in public money for research, but watchdogs are worried about whether the board can distribute the money free of industry influence.
Critics say some of those on the institute's governing board have ties or even personal investments in business or other organizations that could benefit from the money. In addition, the institute's newly approved conflict-of-interest rules are inconsistent and largely self-policing, according to the critics. For instance, board members applied stricter rules to the institute's staff than themselves.
As a result, a panel of state lawmakers today is expected to vote on a proposal that would toughen the institute's conflict-of-interest provisions. It would require the institute's board, employees and science advisers to divest their holdings in firms conducting stem-cell or other biomedical work.
Their bill, SCA 13, backed by a state Senate committee last month, is based on similar rules established by the National Institutes of Health. But the NIH policies themselves are under fire as too draconian and may be softened considerably.
The fact is, there is little...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Sarah Kliff and Azeen Ghorayshi, The New York Times | 07.15.2024
By Katie LaGrone, WPTV | 06.28.2024
Image by National Cancer Institute from Unsplash
TAMPA, Fla. — A Tampa jury recently found the now-defunct Lung Institute in Tampa guilty of engaging in “deceptive or unfair practices” while it offered customers “valueless” stem cell therapy to treat incurable...